Specifically in regard to nausea, it tended to be most pronounced in the first 4 weeks of therapy in all phase III LEAD trials, with symptoms generally dissipating over the remainder of the study period
They restore satiety signals that stopped working properly
The incidence of antibody formation was 44% with exenatide, 8.6% with liraglutide, 69.8% with lixisenatide, 4% with albiglutide, and 1.6% with dulaglutide [48, 103-106]
This data is incredibly helpful for your provider during follow-up consultations

Trump announces major developments in bringing most-favored-nation pricing to American patients, The White House (2025) GLP-1s for weight management, Health Economics and Policy Lab (2025) Weight management medications for chronic use, VA Pharmacy Benefits Management Services and National Formulary Committee (2025) 2025 abbreviated formulary, BlueCross BlueShield Federal Employee Program (2025) 2025 Aetna pharmacy drug guide, Aetna (2025) Cigna Healthcare drug lists for plans offered by employers, Cigna (2025) Things to include in your appeal letter, Patient Advocate Foundation (n.d.) The impact of obesity-related complications on healthcare costs outcomes of a pharmacoeconomic weight loss model, ClinicoEconomics and Outcomes Research (2025) Pharmacotherapy for obesity: recent updates, Clinical Pharmacology (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Investigators use this retatrutide compound to track comprehensive hormonal crosstalk and the long-term maintenance of systemic vigor at a molecular level